by Dimitar Ganev | Aug 29, 2018 | Blog
Due to the 99.6% failure rate of new Alzheimer’s drugs, scepticism is the default attitude in the media coverage of everything around the increasingly occurring disease. To tackle the inevitable reputation hurdles, communication professionals should take advantage...
by Dimitar Ganev | Aug 7, 2018 | Blog
A recent research conducted by PwC and CB Insights found that venture capitalists invested $10.6 billion into healthcare start-ups in the first half of 2018, with $5.3 billion spent in 216 healthcare deals in the second quarter of the year – a 21% increase from the...
by Dimitar Ganev | Jul 27, 2018 | Blog
“Part of our competitors are not only the Novartis of the world and the other pharmas, but really the Amazons and Googles,” Yitzhak Peterburg, the former CEO of pharmaceutical giant Teva, said a year ago, adding that the global healthcare sector is facing a “huge...
by Dimitar Ganev | Jul 13, 2018 | Blog
As the two largest national economies embroil in a trade showdown, it is individual companies which are in the centre of extensive reportages and economic commentary: the dispute is not just between the two countries, but also between corporations and policy makers,...
by Dimitar Ganev | Jul 6, 2018 | Blog
Alongside finance and law, the industry which occupies a central place in the heated Brexit debates is the life sciences. From the infamous campaign bus which hit the road with Vote Leave’s empty promise about £350 million a week for the National Health Service to the...
